StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
GMABBullishEarningsnews
High materiality8/10

Genmab Q3 2026 DARZALEX Sales Boost Royalty Revenue Outlook

Oct 13, 2026, 6:30 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Strong DARZALEX sales underpin GMAB royalty stream; positive for near-term cash flow expectations, though long-term risk from competition remains.

AI summary

What happened, with direct paths to the underlying reporting

Genmab announced Q3 2026 DARZALEX worldwide net trade sales of $4.239B, including US $2.528B and RoW $1.711B. The company collects royalties on J&J's worldwide net sales, signaling stronger near-term royalty cash flow. Ongoing DARZALEX demand supports GMAB's revenue base, though long-term risk from competition remains.

  • DARZALEX Q3 2026 worldwide net trade sales: $4.239B; royalties to Genmab from J&J.
  • US net DARZALEX sales: $2.528B; rest of world: $1.711B.
  • DARZALEX FASPRO (SC) US sales included in totals.
  • Genmab royalty depends on J&J's ongoing DARZALEX demand.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event